NVO vs. RGEN: Novo Nordisk vs. Repligen Stock Comparison

Company Profile

Novo Nordisk (NVO) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVO is classified in Pharmaceuticals while RGEN is classified in Life Sciences Tools & Services.

Repligen (RGEN) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Novo Nordisk (NVO) reports 58.38%, ranking against industry peers normally.

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Novo Nordisk (NVO) reports 33.92%, ranking against industry peers normally.

Novo Nordisk (NVO) at 40.05% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Novo Nordisk (NVO) at 6.43% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Novo Nordisk (NVO) reports EPS growth of 1.77%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

Both Novo Nordisk (NVO) at 0.62 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Repligen (RGEN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Repligen (RGEN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Novo Nordisk (NVO) trades at 10.18 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Repligen (RGEN) at 13.77 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Novo Nordisk (NVO) at 5.43 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics